Skip to main content

Table 2 Summary of mTOR inhibitors in combination with other antitumor drugs

From: mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

mTOR inhibitorsCombined drugApplied tumorThe effectReferences
EverolimusVEGF inhibitor lenvatinibRCCProgression-free survival is significantly extended compared to using them separatelyMotzer et al. [75]
PF-384MEK inhibitor PD-901HNSCCThey inhibit the production of IL-8 and VEGF and the activation of NF-κB and AP-1Mohan et al. [76]
AZD8055HSP90 inhibitor AUY922Breast cancerAZD8055 inhibits the upregulation of HSP70 and HSP27 induced by AUY922, while AUY922 blocks the activation of PI3K/Akt induced by AZD805Chen et al. [78]
RapamycinAR inhibitor enzalutamideHCCRapamycin inhibits the AKT/mTOR signaling pathway activated by enzalutamide, while enzalutamide inhibits the up-regulation of AR expression caused by rapamycinZhang et al. [77]
EverolimusCarboplatin and paclitaxelLCNECThey improve the overall response rate and disease control rateChristopoulos et al. [79]
AZD2014Wee1 inhibitor AZD1775NSCLCAZD2014 enhances the effect of AZD1775 by reducing cyclin D1 to enhance DNA damageHai et al. [80]
  1. AP-1 activator protein 1, AR androgen receptor, HCC hepatic cell carcinoma, HNSCC head and neck squamous cell carcinoma, HSP90 heat shock protein 90, IL-8 interleukin-8, LCNEC large-cell neuroendocrine carcinoma, MEK MAPK/ERK kinase, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, VEGF vascular growth factor